patient with stage G4/A3 CKD should receive the 13-valent pneumococcal [...] vaccine (PCV-13) 1 or more years after the 23-valent pneumococcal polysaccharide vaccine (PPSV-23). A second dose of PPSV-23 should be administered 5 or more years after the first dose.
Answer
conjugate
Question
patient with stage G4/A3 CKD should receive the 13-valent pneumococcal [...] vaccine (PCV-13) 1 or more years after the 23-valent pneumococcal polysaccharide vaccine (PPSV-23). A second dose of PPSV-23 should be administered 5 or more years after the first dose.
Answer
?
Question
patient with stage G4/A3 CKD should receive the 13-valent pneumococcal [...] vaccine (PCV-13) 1 or more years after the 23-valent pneumococcal polysaccharide vaccine (PPSV-23). A second dose of PPSV-23 should be administered 5 or more years after the first dose.
Answer
conjugate
If you want to change selection, open original toplevel document below and click on "Move attachment"
Parent (intermediate) annotation
Open it patient with stage G4/A3 CKD should receive the 13-valent pneumococcal conjugate vaccine (PCV-13) 1 or more years after the 23-valent pneumococcal polysaccharide vaccine (PPSV-23). A second dose of PPSV-23 should be administered 5 or more years after the first dos
Original toplevel document (pdf)
owner: ELBOMBARDO - (no access) - MKSAP_17.pdf, p3429
Summary
status
not learned
measured difficulty
37% [default]
last interval [days]
repetition number in this series
0
memorised on
scheduled repetition
scheduled repetition interval
last repetition or drill
Details
No repetitions
Discussion
Do you want to join discussion? Click here to log in or create user.